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Sterol regulatory element-binding protein (SREBP) transcription factors regulate cellular lipogenesis and lipid
homeostasis. Recent studies reveal expanding roles for SREBPs with the description of new regulatory
mechanisms, the identification of unexpected transcriptional targets, and the discovery of functions for
SREBPs in type II diabetes, cancer, immunity, neuroprotection, and autophagy.Introduction
Membrane-bound, basic helix-loop-helix leucine zipper (bHLH-
LZ) transcription factors called sterol regulatory element-binding
proteins (SREBPs) play a central role in cell metabolism by
controlling synthesis of fatty acids, triglycerides, and cholesterol
(Goldstein et al., 2006). Three mammalian SREBP isoforms
(SREBP-1a, SREBP-1c, and SREBP-2) are encoded by two
genes, SREBF1 and SREBF2, and have distinct but overlapping
lipogenic transcriptional programs. SREBP-1a activates fatty
acid and cholesterol synthesis, SREBP-1c fatty acid synthesis,
and SREBP-2 cholesterol synthesis and uptake (Goldstein
et al., 2006). Early studies focused on the function of SREBPs
in lipid homeostasis and regulation by cholesterol and its oxy-
sterol derivatives. Recently, however, an explosion of studies
demonstrate that SREBPs integrate multiple cell signals to
control lipogenesis as well as unexpected pathways important
for type II diabetes, cancer, the immune response, neuroprotec-
tion, and autophagy. Here, we review current knowledge
regarding regulation of SREBPs and discuss the expanding
cellular roles for these transcription factors.
Signaling to SREBP
Sterol-Dependent Regulation of SREBP
Our understanding of sterol-regulated control of SREBPs comes
largely from the elegant work of Michael Brown, Joseph Gold-
stein, and colleagues at UT Southwestern Medical Center in Dal-
las. Unlike other bHLH-LZ family transcription factors, newly
synthesized SREBPs are inserted into the endoplasmic retic-
ulum (ER) membrane as inactive precursors (Figure 1) (Osborne
and Espenshade, 2009). The SREBP N-terminal bHLH-LZ tran-
scription factor domain is released from the membrane by the
sequential action of the Golgi-localized Site-1 protease (S1P)
and Site-2 protease (S2P). Sterols regulate SREBP by controlling
its ER-to-Golgi transport (Figure 1). Each SREBP isoform binds
the sterol-sensing protein SREBP cleavage-activating protein
(Scap). In cholesterol-poor cells, the SREBP-Scap complex traf-
ficks to the Golgi via COPII vesicles where S1P and S2P proteo-
lytically release the SREBP N terminus (SREBP-N) from the
membrane (Osborne and Espenshade, 2009). In the nucleus,
SREBP-N activates genes involved in cholesterol biosynthesis
and uptake, thus restoring sterol homeostasis. SREBPs are
also self-regulated by transcriptional positive feedback. In addi-
tion, activation of SREBF-1/2 transcription increases expression
of microRNAs-33a/b (miR-33a/b) encoded within introns of the
SREBF2/SREBF1 genes, respectively. miR-33a/b negatively414 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.regulate lipid export and fatty acid oxidation to further aid the re-
turn to homeostasis (Moore et al., 2011). Excess ER cholesterol
binds Scap and elicits a conformational change that promotes
binding of Scap to the ER-resident protein Insig, thus blocking
ER exit of the SREBP-Scap complex (Figure 1). Oxysterol deriv-
atives of cholesterol, such as 25-hydroxycholesterol, accumu-
late under conditions of excess cholesterol and independently
bind to Insig to promote ER retention of SREBP-Scap (Osborne
and Espenshade, 2009). Two genes, INSIG1 and INSIG2, code
for Insig proteins and control tissue- and signal-specific regula-
tion of SREBP transport. Insig-1, but not Insig-2, is subject to
proteasome-dependent degradation, and cholesterol addition-
ally inhibits ER-to-Golgi transport of SREBP by stabilizing Insig-1
(Goldstein et al., 2006). INSIG1 is also a direct SREBP target
gene, and thus SREBP activation increases both cholesterol
levels and Insig-1 protein to provide convergent, negative feed-
back regulation of SREBP-Scap transport and proteolytic activa-
tion. Finally, oxysterols stimulate transcription of SREBP-1c,
which stimulates fatty acid synthesis, through direct binding of
the nuclear hormone receptor liver X receptor (LXR) to the
SREBF1 promoter (Goldstein et al., 2006). Oxysterols are LXR
agonists, and it is proposed that upregulation of SREBP-1c
may serve to increase the supply of unsaturated fatty acids
needed for sterol esterification under conditions of cholesterol
excess.
Insulin-Dependent Regulation of SREBP
The liver is an important site of lipid synthesis and export, and
SREBP-1c plays a major role in the upregulation of fatty acid
synthesis in response to insulin (Osborne and Espenshade,
2009). Insulin activates hepatic SREBP-1c both transcriptionally
and posttranslationally (Figure 1). Insulin-dependent SREBP-1c
transcriptional regulation requires LXR binding elements in the
SREBP-1c promoter, but the detailed mechanism is unknown.
Overexpression of an oxysterol catabolic enzyme, cholesterol
sulfotransferase, abolishes insulin-induced SREBP-1c expres-
sion, suggesting that insulin stimulates SREBP-1c transcription
through LXR activation (Chen et al., 2007). Although both insulin
and the LXR agonist TO-901317 stimulate SREBP-1c transcrip-
tion, only insulin potently activates SREBP target genes, indi-
cating a critical posttranscriptional role for insulin (Goldstein
et al., 2006).
This insulin-stimulated SREBP-1c activation is phosphatidyli-
nositol 3-kinase (PI3K)/Akt dependent, and the mammalian
target of rapamycin (mTOR) kinase is the major PI3K/Akt down-
stream effector (Figure 1). PI3K/Akt activation leads to direct
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Figure 1. Multivalent Regulation of SREBPs
Regulation of SREBPs occurs at the level of
SREBP synthesis, proteolytic activation, tran-
scriptional activity, and degradation. Multiple
signals regulate ER-to-Golgi transport and the
proteolytic activation of SREBPs by controlling the
expression and stability of Insig. In addition,
nuclear SREBPs are highly regulated by post-
translational modification, including phosphoryla-
tion, acetylation, and ubiquitinylation. Positive and
negative regulation are indicated. Abbreviations
are as follows: nuclear form of SREBP, SREBP-N;
unsaturated fatty acids, UFAs; triacylglyceride,
TAG.
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PRAS40, resulting inmTOR complex 1 (mTORC1) activation. The
mTOR inhibitor rapamycin is a commonly used pharmacological
tool to test for mTOR dependence. However, rapamycin inhibi-
tion of mTOR varies among cell types, complicating studies of
insulin’s action on SREBP. For example, rapamycin potently
inhibits insulin-stimulated SREBP activation in primary rat hepa-
tocytes (Li et al., 2010), but higher concentrations fail to block
SREBP activity in mouse NIH 3T3 fibroblasts (Peterson et al.,
2011). Torin-1, a new mTOR inhibitor, potently blocks SREBP
activation in mouse fibroblasts. Collectively, pharmacological
evidence suggests that mTOR mediates insulin-stimulated
SREBP activation.
Genetic mouse model experiments further demonstrate that
mTORC1 is a key regulator downstream of PI3K/Akt. In Tsc1/2
null mouse embryonic fibroblasts (MEFs), mTORC1 is constitu-
tively active and independent of upstream signals. SREBP-1 is
activated in Tsc1/2 null MEFs and activation of SREBP-1 is in-
hibited upon rapamycin treatment, indicating that activation of
mTORC1 is sufficient to stimulate SREBP-1 activity (Du¨vel
et al., 2010). Similarly, inactivation of mTORC1 is sufficient to
shut down SREBP-1 and lipogenesis. Hepatic inactivation of
mTORC1 by knockout of the Raptor subunit protects mice
from hepatic steatosis induced by a high-fat and high-choles-
terol diet (Peterson et al., 2011). Inhibition of S6 kinase, a down-
stream target of mTORC1, blunts SREBP-1 processing in Tsc1/2
null MEFs (Du¨vel et al., 2010) but fails to block insulin-induced
SREBP-1c activation in primary rat hepatocytes (Li et al.,
2010), suggesting the existence of S6-kinase-independent
SREBP-1c regulation by mTORC1. Collectively, these mouse
and cultured cell studies implicate a novel downstream target
of mTORC1 in regulation of SREBP-1c activity (Krycer et al.,
2010).
A recent study revealed that lipin-1, a phosphatidic acid phos-
phatase and a transcriptional coactivator, is a direct substrate of
mTORC1 and a regulator of nuclear SREBP activity (Peterson
et al., 2011). Lipin-1 phosphorylation by mTORC1 blocks its
nuclear localization and activates SREBP (Figure 1). Conversely,Cell Metabolism 16expression of a nonphosphorylated form
of lipin-1 results in lipin-1 nuclear localiza-
tion, reduced levels of nuclear SREBP,
and altered localization of SREBP to the
nuclear periphery. Finally, knocking
down lipin-1 in liver-specific Raptor
knockout mice restores SREBP-1 activa-tion. This study implicates lipin-1 as an insulin-dependent,
mTORC1 downstream effector that regulates SREBP activity
(Peterson et al., 2011). Interestingly, SREBP-1 directly activates
LPIN1 transcription in human hepatoblastoma cells, providing
a possible mechanism for negative feedback regulation of
SREBP-1 activity (Csaki and Reue, 2010).
Lipin-1 is both a phosphatidic acid phosphatase required for
triglyceride synthesis and a transcriptional coactivator essential
for adipose tissue development (Csaki and Reue, 2010). These
dual functions complicate its study. How lipin-1 inhibits
SREBP-1 activity and whether lipin-1 acts directly are unknown,
but inhibition requires lipin-1 catalytic activity (Peterson et al.,
2011). This finding is interesting, as the enzymatic function of
lipin-1 was previously thought to be limited to the conversion
of phosphatidic acid to diacylglycerol for triglyceride and phos-
pholipid synthesis in the cytosol. Further studies are needed to
understand this nuclear, catalytic function of lipin-1. To date,
studies of lipin-1 function have been carried out largely in
adipose tissue, where lipin-1 is the major phosphatidic acid
phosphatase. However, lipin-1 is not the major enzyme in the
liver, where two additional enzymes, lipin-2 and lipin-3, are ex-
pressed (Csaki and Reue, 2010). The finding that lipin-1 nega-
tively regulates SREBP-dependent lipogenic gene expression
should stimulate detailed studies of the hepatic function of
the three Lpin genes and their impact on regulation of hepatic
lipogenesis. Consistent with this newly discovered role for
lipin-1, fatty acid synthesis was found to be upregulated in
Lpin1/ mice (Csaki and Reue, 2010). This new connection
between SREBP and lipin-1 links two important regulators of
lipid homeostasis and adds a new player to the list of SREBP
regulators.
Insulin regulates SREBP activity through additional mecha-
nisms other than LXR-dependent transcription and lipin-1.
Inhibition of PI3K by chemical inhibitors or expression of a domi-
nant-negative Akt inhibits SREBP ER-to-Golgi transport and
proteolytic activation (Krycer et al., 2010). Consistent with this,
insulin stimulates ER-to-Golgi transport of SREBP-1c by
promoting its phosphorylation and association with COPII, October 3, 2012 ª2012 Elsevier Inc. 415
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Figure 2. SREBPs Integrate Multiple Signals to Control Tissue-
Specific Gene Expression
SREBP transcription factors respond to diverse environmental signals such as
lipid supply, nutrients (via insulin), and inflammatory signals. The signals to
SREBP and the target genes that SREBP activates are tissue dependent. For
example, in the liver, SREBPs respond to lipid supply and insulin to control lipid
metabolism. While in macrophages of the immune system, SREBP responds
to inflammatory signals to promote lipid metabolism and the immune
response.
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is additionally regulated by Akt signaling through control of
Insig-2 levels (Figure 1). Two differentially regulated mRNA tran-
scripts (Insig-2a and Insig-2b) code for Insig-2, and Insig-2a is
the predominant hepatic transcript (Goldstein et al., 2006).
Insulin negatively regulates expression of Insig-2a mRNA in an
Akt-dependent manner, resulting in a decreased Insig protein
pool and increased ER-to-Golgi transport of SREBP (Yecies
et al., 2011). Overall, insulin acts at multiple regulatory steps to
control activity of SREBPs.
Additional Signals to SREBPs
Sterols control ER-to-Golgi transport of SREBP by regulating
Scap binding to Insig, but additional signals alter ER exit to
control SREBP activity (Figure 1). Unsaturated fatty acids
decrease the proteolytic processing of SREBP-1 by stabilizing
Insig-1 (Lee et al., 2008). In neurons, N-methyl-D-aspartate
glutamate receptor (NMDAR) overactivation results in the accel-
erated degradation of Insig-1, promoting the ER-to-Golgi trans-
port and proteolytic activation of SREBP-1 (Taghibiglou et al.,
2009). ER stress also promotes the ER exit of SREBPs by
decreasing Insig-1 (Osborne and Espenshade, 2009). Overex-
pression of GRP78, an ER chaperone, in the livers of genetically
obese ob/ob mice reduces ER stress, blocks SREBP-1 pro-
cessing, and prevents hepatic steatosis (Kammoun et al.,
2009). In these insulin-resistant mice, Akt activity is attenuated.
Thus, this study suggests that ER stress may serve as an alter-
native path to SREBP activation independent of Akt. Finally,
bacterial pore-forming toxin treatment activates SREBPs by
stimulating cellular potassium efflux, which promotes ER-to-
Golgi transport of both SREBP-1 and -2 (Osborne and Espen-
shade, 2009). In cases for which a mechanism has not been
determined, the possibility exists that these signals regulate
SREBP indirectly by changing sterol levels similar to how
oxygen signals to SREBP in fungi (Osborne and Espenshade,
2009).
SREBP may also be regulated in an ER-to-Golgi transport-
independent manner. Recently Na¨a¨r and colleagues discovered
that blocking phosphatidylcholine (PC) synthesis stimulates the416 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.proteolytic activation of SREBP-1 (Walker et al., 2011). An inter-
esting model emerged from this study in which Golgi-localized
S1P and S2P translocate from the Golgi to the ER upon the
depletion of PC. Although further studies are needed, this study
indicates that SREBP cleavage could be activated in the
absence of ER-to-Golgi transport by controlling the localization
of S1P and S2P.
Proteolytically activated, nuclear SREBPs integrate signals
from multiple pathways through posttranslational modifications
including phosphorylation, ubiquitinylation, and acetylation
(Figure 1). In cultured cells, insulin additionally signals to SREBP
through Akt inhibition of GSK3, which directly phosphorylates
SREBP-1c (Krycer et al., 2010). In the absence of Akt signaling,
GSK3 phosphorylates SREBP leading to ubiquitinylation by the
SCF(Fbw7) ubiquitin ligase and proteasomal degradation of the
active transcription factor. While liver-specific knockout of
Fbw7 in mice resulted in steatohepatitis, the observed accumu-
lation of liver triglyceride does not require SREBP-1, suggesting
that this Fbw7 degradative mechanism may function in nonhe-
patic tissues (Kumadaki et al., 2011). The nutrient sensor AMP-
activated protein kinase (AMPK) negatively regulates SREBP to
limit lipogenesis under nutrient-limiting conditions by directly
phosphorylating SREBP (Li et al., 2011). Finally, SIRT1 deacety-
lation of SREBP-1c increases its degradation and is regulated
by feeding in mice (Walker et al., 2010). Transcriptional coactiva-
tors and cooperating transcription factors provide yet another
level of regulatory control of SREBPactivity (Osborne andEspen-
shade, 2009). Collectively, combined regulation of SREBP tran-
scription, proteolytic activation, and nuclear activity allow
SREBPs to integrate nutrient signals from multiple pathways to
control metabolism.
Emerging Functions for SREBP
Maintaining lipid homeostasis is essential for cell viability. Given
their critical role in this process, SREBPs likely function in all
cells. Hepatocytes are normally nondividing and frequently
challenged by fluctuations in lipid supply and demand. Thus in
the liver, lipids and insulin are the dominant signals to SREBP
for control of lipogenesis (Figure 2). However, in nonhepatic
cells, lipid levels may not change dramatically, thereby mini-
mizing the sterol-dependent regulation of SREBP. In these
settings, other signals may dominate, revealing new modes of
sterol-independent regulation of SREBP (Figure 2). SREBP
frequently cooperates with additional transcription factors,
providing a mechanism for this tissue-specific, SREBP-depen-
dent gene expression (Osborne and Espenshade, 2009).
Consistent with this, the application of ChIP-Seq technology
to the SREBP pathway has revealed that SREBPs control tran-
scriptional programs extending beyond lipid synthesis. In
addition, the detailed understanding of SREBP function in lipo-
genesis has led to studies of SREBP function in the context of
disease states.
Type II Diabetes
The incidence of type II diabetes mellitus has increased due to
the obesity epidemic, and diabetes is projected to affect one-
quarter of the U.S. population by 2050. Type II diabetes is
characterized by hyperinsulinemia, hyperglycemia, and hypertri-
glyceridemia with associated fatty liver (hepatic steatosis), which
can lead to cirrhosis and eventual liver failure. Insulin regulation
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induces fatty liver suggest that SREBPs play a central role in
development of hepatic steatosis. Indeed, Horton and
colleagues recently demonstrated that SREBPs are essential
for hepatic steatosis in genetic and dietary rodent models of
obesity (Moon et al., 2012). Liver-specific knockout of the
SREBP transport protein Scap eliminates activity of all three
SREBP isoforms and prevents steatosis in ob/ob mice and
mice on a high-fat diet. In addition, hepatic knockdown of
Scap by siRNA suppresses carbohydrate-induced hypertrigly-
ceridemia in hamsters, demonstrating the therapeutic potential
of SREBP pathway inhibition. Interestingly, evidence exists
that SREBPs in turn can regulate insulin signaling (Figure 1).
Insulin receptor substrate 2 (IRS-2) is a major mediator of insulin
signaling in the liver, controlling insulin sensitivity. Nuclear active
SREBPs can decrease IRS-2 expression, inhibit the downstream
PI3K/Akt pathway, and decrease glycogen synthesis (Ide et al.,
2004). Consistent with this, high SREBP-1c activity resulting
from hyperinsulinemia negatively correlates with IRS-2 expres-
sion in ob/ob mice (Goldstein et al., 2006). These data suggest
that the SREBP pathway may contribute to liver insulin resis-
tance; however, data from the liverScap knockout study indicate
otherwise. Liver-specificScap knockout prevented hepatic stea-
tosis, but loss of SREBP activity had no effect on liver insulin
resistance (Moon et al., 2012). More work is required to fully
understand the mechanisms underlying differential insulin
signaling in the liver.
Cancer
Cancer cells are a new cell type with distinct properties
compared to other cells in the body. Increased de novo lipid
synthesis is one hallmark of cancer (Krycer et al., 2010). Consis-
tent with this lipogenic character, the expression of several
SREBP target genes such as fatty acid synthase and LDL
receptor are elevated in tumor cells. Since cancer cells need to
maintain lipid supply to support tumor growth and SREBPs are
master regulators of lipogenesis, SREBP activity is likely
required for tumor growth, making the SREBP pathway a poten-
tial target for anticancer therapy. Studying glioblastoma, Mischel
and colleagues demonstrated that epidermal growth factor
receptor mutations (EGFRvIII) and hyperactivation of PI3K
promote tumor growth and survival through stimulation of
SREBP-1 activity. Blocking tumor cell cholesterol supply by
decreasing uptake through the LDL receptor promotes tumor
cell death in vivo (Guo et al., 2011). Although not directly target-
ing SREBPs, this study demonstrates that targeting lipid supply
is a potential strategy to treat cancer. Considering that SREBPs
control sterol uptake as well as de novo synthesis, inhibition of
SREBP activity could be a more promising strategy.
Recently, direct connections between the tumor suppressor
p53 and SREBP have been discovered. The p53 gene, TP53, is
the most frequent target for mutation in tumors (>50% of human
cancers exhibit mutations in TP53). The majority of TP53 muta-
tions are missense mutations that result in expression of mutant
p53 with a prolonged half-life and gain-of-function activity
(Freed-Pastor et al., 2012). Using a 3D culture breast cancer
model, Prives and colleagues demonstrated that mutant p53
promotes lipid synthesis through the mevalonate pathway to
support themalignant phenotype. Data suggest that p53 associ-
ates with promoters of lipid enzymes through association withSREBP and that the mevalonate pathway is a possible thera-
peutic target in tumors bearing p53 mutations. Together, these
findings suggest that SREBPs may play an important function
in tumorigenesis and highlight the SREBP pathway as a potential
target for anticancer therapy.
Immune System
In the immune system, phagocytosis is a major mechanism used
to remove pathogens such as bacteria. Phagocytosis requires
membrane biogenesis to compensate for the loss of plasma
membrane wrapped around the engulfed particles. Phagocy-
tosis promotes membrane biogenesis by activating processing
of both SREBP-1a and -2 (Osborne and Espenshade, 2009).
SREBPs are also activated upon bacterial toxin challenge.
SREBP-1a directly activates expression of the antiapoptotic
gene Api6 upon toxin challenge to promote cell survival (Im
and Osborne, 2012).
Compared to SREBP-1c, expression of SREBP-1a in meta-
bolic tissues is relatively low, and its physiological regulation is
largely unknown. Recently, Osborne and colleagues found that
SREBP-1a is highly expressed in cells of the immune system,
such as macrophages and dendritic cells (Im et al., 2011). In
wild-type macrophages, lipopolysaccharide (LPS) treatment
stimulates lipogenesis, but macrophages isolated from
SREBP-1a-deficent mice fail to activate expression of lipogenic
genes in response to LPS. Analysis of the SREBP-1a promoter
identified an NF-kB binding element flanked by two Sp1 binding
sites. Chromatin immunoprecipitation (ChIP) experiments in
macrophages indicate that LPS enhances NF-kB/Sp1 activation
of the SREBP-1a promoter to increase lipogenesis. In addition,
SREBP-1a activates expression of Nlrp1, a core component of
the inflammasome, and SREBP-1a-deficient mice display a
defective inflammatory response, showing resistance to toxic
shock but sensitivity to Salmonella infection (Im et al., 2011).
Autophagy
Autophagy is a lysosomal degradative pathway that functions to
remove and breakdown cellular components, such as organelles
and proteins. Autophagy also mediates the breakdown of lipids
stored in lipid droplets. A genome-wide SREBP-2 ChIP-Seq
analysis in mouse liver revealed that SREBP-2 occupies
promoters of genes involved in autophagy (Seo et al., 2011). In
cholesterol-depleted cells, knocking down SREBP-2 decreases
autophagosome formation and lipid droplet association of the
autophagosome protein LC3. These data provide evidence for
regulation of autophagy by SREBP-2.
Neuroprotection
Neuronal excitotoxicity caused by overactivation of NMDARs is
a primary neuropathological process contributing to neuronal
injury after stroke and brain trauma. Activation of SREBP-1 is
an essential step in NMDAR-mediated excitotoxic neuronal
death (Taghibiglou et al., 2009). Overactivation of NMDARs
stimulates SREBP-1 processing by accelerating the degrada-
tion of Insig-1. Systemic administration of Insig-1-derived inter-
ference peptide (Indip) blocked Insig degradation and
suppressed SREBP-1 activation, reducing neuronal damage in
a rat stroke model. How activation of SREBP-1 promotes
neuronal damage remains to be determined, but targeting
SREBP-1 downstream of NMDARs may be a neuroprotective
strategy in stroke. SREBP-1 also regulates parasympathetic
stimulation of the heart, which provides protection fromCell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc. 417
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tion, the G protein-coupled inward-rectifying K+ channel
GIRK1/4 is activated, generating acetylcholine-sensitive K+
current (IKACh). In embryonic chick atrial myocytes, SREBP-1
activates IKACh through direct binding to the GIRK1 promoter
and control of its expression (Park et al., 2008). Compared to
wild-type animals, SREBP-1 knockout mice show both reduced
GIRK1 expression and a reduced cardiac response to parasym-
pathetic stimulation. Together, these data implicate SREBPs in
neuronal physiology.Future Challenges
Initial studies of the SREBPpathway combined powerful somatic
cell genetic approaches in Chinese hamster ovary cells and
in vivo experiments in mouse liver to identify pathway compo-
nents and understand their regulation. In the past decade, new
tools and techniques have facilitated studies in nonhepatic
tissues demonstrating that SREBPs play a broader role in
metabolism. Given their role as regulators of essential lipid
homeostasis, SREBPs likely function in all cells. The diverse
mechanisms for SREBP regulation provide ample opportunity
for context-specific regulation of SREBP, and one future chal-
lenge is to understand the tissue-specific regulation and function
of the SREBP-1a, -1c, and -2 isoforms. Cataloging SREBP tran-
scriptional targets in different tissues is an important first step.
That we are only beginning to understand the scope of SREBP
function is highlighted by the studies of SREBP-1a in the immune
system (Im et al., 2011) and the discovery of miR-33a/b regula-
tion of lipid homeostasis (Moore et al., 2011). To date, the central
role for SREBPs in the expression of the LDL receptor and the
cholesterol-lowering effects of statin drugs has stimulated
research in the SREBP field due to therapeutic implications for
cardiovascular disease. Emerging data suggest that continued
study of the SREBP pathway will advance efforts to combat
diseases such as diabetes, hepatic steatosis, and cancer.
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